The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | Practice-changing findings in MPNs from ASCO 2025
In this video, Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, briefly comments on the practice-changing findings in the field of myeloproliferative neoplasms (MPNs) from the 2025 ASCO meeting. He highlights the VERIFY trial (NCT05210790), which aims to reduce the need for phlebotomy in patients with polycythemia vera (PV) using the hepcidin mimetic rusfertide, and the SURPASS ET study (NCT04285086), which shows the superiority of ropeginterferon alfa-2b over anagrelide in essential thrombocythemia (ET), offering a new therapeutic option for patients. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think there’s two main practice changing things in myeloproliferative neoplasms at ASCO this year. The first of which is the VERIFY trial, which we presented as a late-breaking abstract in the plenary session today. This is looking at rusfertide’s ability to reduce the need for phlebotomy in patients with polycythemia vera. In addition to that, what we’re going to see is a clinical trial looking at ropeginterferon in patients that have essential thrombocythemia or ET called the SURPASS ET study...
I think there’s two main practice changing things in myeloproliferative neoplasms at ASCO this year. The first of which is the VERIFY trial, which we presented as a late-breaking abstract in the plenary session today. This is looking at rusfertide’s ability to reduce the need for phlebotomy in patients with polycythemia vera. In addition to that, what we’re going to see is a clinical trial looking at ropeginterferon in patients that have essential thrombocythemia or ET called the SURPASS ET study. We often use interferons in patients that have ET, but we haven’t been able to use ropeginterferon to this day. And so ropeginterferon was looked at as a second line agent in the treatment of patients with ET randomized against anagrelide and we saw superiority of the ropeginterferon against anagrelide in these patients with essential thrombocythemia. Now allows us to have that option for these folks. Right now ropeg is already approved for polycythemia vera but to be able to use it in our ET patients I think will come as a welcome addition.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
